<DOC>
	<DOCNO>NCT00308854</DOCNO>
	<brief_summary>The aim study investigate whether PD P 506 A-PDT effective treating mild moderate AK lesion locate head .</brief_summary>
	<brief_title>Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT Treatment AK</brief_title>
	<detailed_description>Actinic keratosis ( AK ) pre-cancerous skin abnormality usually cause sun exposure . Actinic keratoses occur commonly fair skin , especially elderly . They mainly occur sun-exposed skin area like head hand . It standard care remove AK diagnose , achieve either physical ablation , chemotherapeutic agent photodynamic therapy ( PDT ) . A direct comparison versus placebo necessary exact quantification effect PD P 506 A yet perform subject study protocol .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Written inform consent Caucasian patient Diagnosis actinic keratosis ( AK ) least three locally separate lesion locate head and/or face ( hairless area ) Selected AK study lesion clearly define margin mild moderate The distance study lesion border &gt; 1.0 cm Maximum diameter study lesion 1.8 cm Skin sun sensitivity type I IV accord Fitzpatrick PDT Nonresponder Pretreatment AK lesion eligible study procedure pharmaceutical approve treatment AK 4 week precede PDT Pretreatment AK lesion eligible study procedure 2 week precede PDT keratolytic agent e.g . TCA , urea salicylic acid contain formulation Pretreatment hypericin 2 week precede PDT Treatment systemic retinoids 3 month precede PDT Treatment cytostatics radiation 3 month precede PDT Female patient childbearing potential Patients clinically relevant suppression immune system Diagnosis Porphyria Skin disease might interfere response evaluation study PDT Skin sun sensitivity type V VI accord Fitzpatrick Known intolerance one ingredient study medication Dementia psychic condition might interfere ability understand study thus give write informed consent Simultaneous participation another clinical study participation another clinical study 30 day directly precede inclusion Suspected lack compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>AK</keyword>
	<keyword>PDT</keyword>
</DOC>